AlphaCentric Advisors’s UroGen Pharma URGN Stock Holding History

AlphaCentric Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-143,898	Closed	-$2.16M	–	256
2024 Q1	$2.16M	Sell	143,898 -11,102	-7%	-$181K	1.3%	20
2023 Q4	$2.33M	Sell	155,000 -10,000	-6%	-$130K	1.56%	16
2023 Q3	$2.31M	Buy	165,000 +12,500	+8%	+$201K	1.31%	20
2023 Q2	$1.58M	Buy	+152,500	New	+$1.68M	0.88%	42

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

AlphaCentric Advisors's URGN Position: Q2 2024 in Review

AlphaCentric Advisors sold out of UroGen Pharma (URGN) in Q2 2024, closing a stake of 143,898 shares — an estimated $2.16M sold.

AlphaCentric Advisors first reported a position in URGN in Q2 2023 and held it in 4 quarters. The position peaked at $2.33M in Q4 2023. 115 funds tracked by Wall St. Rank hold URGN as of Q2 2024.

AlphaCentric Advisors reported no remaining UroGen Pharma position as of Q2 2024 after selling out during the quarter.
AlphaCentric Advisors sold 143,898 UroGen Pharma shares in Q2 2024, an estimated $2.16M.
AlphaCentric Advisors first reported a position in UroGen Pharma in Q2 2023 and held it in 4 quarters.
AlphaCentric Advisors's UroGen Pharma position peaked at $2.33M in Q4 2023.
115 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2024.

Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.